Malinin, Nikolay L.
Lee, GaHyun
Lazzarotto, Cicera R. http://orcid.org/0000-0003-1093-0175
Li, Yichao http://orcid.org/0000-0001-5791-096X
Zheng, Zongli
Nguyen, Nhu T.
Liebers, Matthew
Topkar, Ved V.
Iafrate, A. John
Le, Long P.
Aryee, Martin J. http://orcid.org/0000-0002-6848-1344
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
Tsai, Shengdar Q. http://orcid.org/0000-0001-9161-3993
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01AI157189)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM088040)
Doris Duke Charitable Foundation (2017093)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063070)
Article History
Received: 31 October 2020
Accepted: 2 September 2021
First Online: 12 November 2021
Competing interests
: S.Q.T. is a co-inventor on patents covering the GUIDE-seq method. S.Q.T. is a member of the scientific advisory board of Kromatid and Twelve Bio. M.J.A. and J.K.J. hold equity in SeQure Dx, Inc. J.K.J. holds equity in Chroma Medicine. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a co-inventor on various patents and patent applications that describe gene editing and epigenetic editing technologies, including the GUIDE-seq method.